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Objectives. This study sought to characterize the effects of 
prolonged catecholamine infusion on immunoregulatory cell traf- 
fic and activation. 
Background. Immunoregulation has been shown to be partially 
controlled by the sympathetic nervous system. Although short- 
term elevation of catecholamine levels is known to alter immuno- 
regulatory cell traffic and activation, the effects of prolonged 
heightened sympathetic nervous system activity have not ade- 
quately been studied. We believe that the alterations in immune 
function seen in patients with congestive heart failure are linked 
to a prolonged elevation of circulating catecholamine levels. 
Methods. To characterize the effects of prolonged elevation of 
catecholamine levels, rats received 4weeks of constant infusion of 
epinephrine or norepinephrine through implanted osmotic 
minipumps. Peripheral and splenic leukocyte subsets, T cell 
proliferation and interleukin-2 receptor expression were quanti- 
fied. Antibody production to the novel antigen keyhole limpet 
hemocyanin was assessed over the 4-week treatment period. 
Results. Both epinephrine and norepinephrine caused signifi- 
cant splenic atrophy and cardiac hypertrophy; both were blocked 
by propranoiol. Epinephrine induced lymphocytosis; both cat- 
echolamines caused an increase in natural killer cells. In the 
spleen, both epinephrine and norepinephrine l d to a dose- 
dependent decrease in total T cells, suppressor/cytotoxic T ells 
and natural killer cells and a significant increase in B cells. 
Epinephrine at the low dose enhanced mitogen-induced prolifer- 
ation and interleukin-2 receptor expression. Norepinephrine at 
the low dose appeared to diminish proliferation. Epinephrine 
tended to inhibit IgG antibody production, whereas norepineph- 
rine had no effect. 
Conclusions. The results of our study indicate that prolonged 
elevation of catecholamine levels alters immune cell proliferation 
and differentiation. These alterations differ greatly from those 
induced by short-term stimulation but, for the most part, parallel 
those found in patients with congestive heart failure. We postulate 
that the shifts in immunoregulatory cell type and function seen in 
patients with congestive heart failure are due, in part, to long- 
standing increases in circulating catecholamine l vels and may 
play an important role in the pathogenesis and progression of 
disease. 
(J Am CoU Cardiol 1995;26:102-9) 
Previous studies have shown that immune function is partially 
regulated by the sympathetic nervous system (1-6). Pharma- 
cologic agents that mimic or modulate sympathetic neurotrans- 
mitter activity have been used to alter immune activation, both 
in vivo and in vitro (1,6-10). Many lymphoid organs, especially 
the spleen, thymus and lymph nodes, are densely innervated by 
noradrenergic fibers (1). The extensive presence of surface 
receptors for sympathetic neurotransmitters indicates that 
lymphocytes are subject o sympathetic stimulation. Short-term 
elevation of catecholamine l vels, whether by exhaustive xer- 
cise (11-22), injection of adrenergic agonists (7,8,12,23-25) or 
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acute myocardial infarction (26-28), alters immunoregulatory 
cell traffic and activation. 
The effects of prolonged heightened sympathetic nervous 
system activity have not been adequately studied. Patients with 
congestive heart failure have both elevated catecholamine 
levels and alterations in immune function (29-34), suggesting 
a possible link between the two. In the present study, rats 
received a constant infusion of epinephrine or norepinephrine, 
the two circulating catecholamines most commonly elevated in 
patients with congestive heart failure. In addition, the nonse- 
lective beta-adrenergic blocking agent propranolol was infused 
simultaneously with epinephrine to isolate the effects from 
alpha- and beta-receptors. 
Methods  
Rats. Male Sprague-Dawley rats (Harlan Sprague-Dawley) 
were kept two to a cage in a climate-controlled nvironment 
with 12-h light/dark schedules and allowed to acclimate for 
1 week. They then underwent a minor surgical procedure for 
implantation of osmotic minipumps (Alza Co.) containing 
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either vehicle or drug. The pumps contained either epineph- 
rine (100 to 200 ~g/kg body weight per h) with 10 mmol/liter of 
hydrochloric acid as the vehicle or norepinephrine (100 to 
200/~g/kg per h) with 20% ascorbic acid as the vehicle. Some 
rats with epinephrine also received pumps containing the 
beta-blocker propranolol (400 /~g/kg per h). The rats were 
anesthetized with ketamine (75 mg/kg intramuscularly) and 
xylazine (5 mg/kg intramuscularly). A small incision was made 
in the nape of the neck, followed by subcutaneous pocket 
formation, pump implantation and wound closure with two 
staples. Rats were killed after 4 weeks. Anesthesia was deliv- 
ered as previously described, and spleens were removed and 
weighed. Peripheral blood was rapidly obtained by cardiac 
puncture into the right ventricle and was anticoagulated with 
ethylenediaminetetracetic acid (EDTA). The hearts were ex- 
cised and weighed. 
Leukocyte isolation. Peripheral leukoo,tes. Up to 10 ml of 
peripheral blood was obtained by cardiac puncture. A l-ml 
sample was placed in a vacutainer containing EDTA and sent 
for automated complete blood count with differentials. The 
remaining blood was anticoagulated with 0.5 tool/liter of 
EDTA solution (5 mmol/liter final) and diluted with phosphate 
buffered saline (PBS). Ficoll-Paque was subfused, and the 
resulting suspension was centrifuged at 1,400 rpm for 60 rain. 
Lymphocytes were collected at the FicolI-PBS interface and 
washed three times at 1,200 rpm for 15 rain. Cells were 
resuspended and counted on a hemacytometer. 
Splenocytes. Spleens were removed intact and teased apart 
in PBS using sterile technique. Ficoll-Paque was subfused, and 
the resulting suspension was centrifuged at 1,600 rpm for 
30 rain. Splenocytes were collected at the FicolI-PBS interface, 
washed twice at 1,400 rpm for 15 min, resuspended in RPMI 
1640 supplemented with 20% fetal bovine solution, 25/xg/ml of 
gentamicin and 2 mmol/liter of glutamine and counted on a 
hemacytometer. More than 90% of the splenocytes and leuko- 
cytes were viable as assessed by Trypan blue exclusion. 
Immunofluorescent lymphocyte subtyping. Both direct and 
indirect immunofluorescence w re required to label the vari- 
ous lymphocyte subpopulations. Splenocytes and peripheral 
lymphocytes were diluted to a concentration of 15 x 100 
cells/ml with PBS plus 0.1% sodium azide. Multiple aliquots of 
cells were labeled with fluorescein isothiocyanate (FITC)- 
conjugated mouse anti-rat monoclonal antibodies (Bioprod- 
ucts for Science) against total T cell (W3/13), suppressor/ 
cytotoxic T cell (MRC OX-8), helper T cell (W3/25) and 
natural killer cell (CD16) determinants. Indirect staining was 
required for detection of the B cell population. The primary, 
antibody was mouse anti-rat leukocyte common antigen 
(L-CA) (MRC OX-33) present on B cells; the secondary. 
antibody was F(ab')2 rabbit anti-mouse IgG-FITC conjugate. 
The cells were incubated on ice for 30 rain in the dark and 
washed twice at 1,600 rpm for 10 rain. The tagged cells were 
fixed with 1% formaldehyde and stored at 4°C until analyzed. 
Immunofluorescence wasmeasured with a flow cytometer 
(Ortho Cytofluorograf 50-H) equipped with a 5-W argon laser 
and interfaced with a model 2150 computer (Data General). 
Data analysis was performed with software provided by Ortho. 
Five thousand cells were analyzed per sample. Electronic 
gating of the lymphocyte population was based on forward and 
side-scatter variables. Percent positive fluorescence of the 
gated population was determined relative to the fluorescence 
of negative controls. The relative proportion of each subset 
was obtained as a percentage ofthe lymphocytes counted, and 
the absolute number in each subset was calculated by multi- 
plying the percentage of each subset by the absolute lympho- 
cyte count derived from the automated complete blood count. 
Concanavalin A mitogen-stimulated proliferation/tritiated 
thymidine uptake. Sterile isolated mononuclear leukocytes 
(MNLs) from the spleen were resuspended in supplemented 
RPMI 1640 and placed in sterile 96-well flat-bottom plates at 
a final concentration of 2 × 106 cells/ml. Either buffer or 
Concanavalin A (Con A) at 0.5, 1, 2, 4 or 8 pg/ml was added 
to each well. Cells were incubated for 72 h in a 37°C humidified 
incubator with 5% carbon dioxide/95% air. Sixteen hours 
before the end of incubation, 2/sCi of tritiated thymidine was 
added to each well. The cells were harvested over GF/C filter 
paper with a cell harvester (Brandel). The incorporated radio- 
activity was quantified in a liquid scintillation counter using 
4.5 ml of Liquiscint. Each data point was assessed in quadru- 
plicate. 
Concanavalin A mitogen-stimulated interleukin-2 receptor 
production. Sterile isolated MNLs from the spleen were sus- 
pended in supplemented RPMI media in the presence and 
absence of Con A (4 >g/ml). After 72 h, the cells were 
centrifuged and resuspended in PBS plus 0.1% sodium azide. 
The expression of interleukin-2 receptors was determined 
cytofluorometrically using a CD25 monoclonal antibody 
(PharMingen). 
Anti-keyhole limpet hemocyanin lgG antibody response. 
One day after pump implantation, rats were immunized with 3 
to 10 >g/kg of keyhole limpet hemocyanin (KLH) (Calbio- 
chem) by intraperitoneal injection. Plasma samples were col- 
lected by tail venipuncture twice a week for 4 weeks. Anti-KLH 
IgG antibody levels were quantified by enzyme-linked immu- 
nosorbant assay (ELISA). In this assay, a plasma sample was 
incubated for 4 h in a 96-well plate coated with KLH. 
The serum was washed from the plate, and an alkaline 
phosphatase-conjugated F(ab')2 fragment goat anti-rat anti- 
body against IgG (Fc fragment specific) was added to each well 
and incubated overnight. The plate was washed again; 1 mg/ml 
of p-nitrophenyl phosphate was added, and the spectrophoto- 
metric reaction was measured 60 rain later with an automatic 
plate reader (Titertek Multiskan PLUS, Labsystems, Helsinki, 
Finland) at 405 nm. 
Catecholamine levels. Plasma catecholamine levels were 
measured radioenzymatically b the method of Durrett and 
Ziegler (35). 
Data analysis. Results are mean value + SEM. The signif- 
icance of between-group differences was determined by un- 
paired two-tailed t tests using Bonferroni corrections or anal- 
ysis of variance to correct for multiple comparisons. 
104 I tARRIS ET AL. JACC Vo l .  26 ,  No .  1 
CATECt lO I .AMINE ELEVATION AND IMMUNE FUNCTION July /995:102-9 
40 
3.5 
3.0 
2.5 
20 
15 
LO 
Spleen/body Heart/body 
Figure l. Comparison of the effects of low (100/xg/kg per h [hatched 
bars]) and high (200 ,ag/kg per h [solid bars]) dose epinephrinc 
infusion, as well as epinephrine plus propranolol infusion (Prop/epi 
[crosshatched bars]), on splenic atrophy and cardiac hypertrophy, as 
measured by spleen/body weight ratios and heart/body weight ratios. 
Control rats received vehicle (open bars). Results are mean value + 
SEM (rag tissue/g body weight). Two-tailed t tests with Bonferroni 
corrections arc discussed in text. 
Results 
Epinephrine infusion. Infusion of epinephrine caused 
dose-dependent atrophy of the spleen (Fig. 1) and diminution 
of splenic cclls recovered aftcr the rats were killed (data not 
shown). It also led to an increase in heart/body weight ratio 
(3.07 -+ 0.05 mg/g in thc control group vs. 3.27 + 0.05 mg/g in 
the low dose group vs. 3.57 + {_1.12 mg/g in the high dose group, 
p < (t.001) (Fig. 1). This hypertrophy was partly mitigated by 
the concomitant infusion of propranolol. 
Both serum dopamine and epinephrine l vels were elevated 
after epinephrine infusion (424 _+ 498 vs. 1,027 _+ 460 pg/ml for 
dopamine and 2,208 _+ 1,549 vs. 3,494 _+ 1,812 pg/ml for 
epinephrine in the control and infusion groups, respectively.) 
Norepinephrine levels were similar in both groups (control 
group 515 _+ 121 pg/ml vs. infusion group 482 _+ 105 pg/ml). 
In the spleen, epinephrine infusion led to a dose-dependent 
reduction in percent of T cells (low dose 7%, p = 0.03; high 
dose 19%, p = 0.004) (Fig. 2a). Subsets affected included a 
marked decrease in suppressor/eytotoxic T cells and a tendency 
to a decrease in helper T cells (Fig. 2, b and c). There was a 
dose-dependent reduction of natural killer cells (low dose, A = 
22°4, p = 0.009; high dose, A = 35%, p = 0.01) (Fig. 2d). In 
contrast to T cells, B cells showed a large increase in both 
epinephrine groups (low dose, A = 41%, p = 0.0001; high 
dose, A = 48%, p = 0.003) (Fig. 2el. The administration of 
propranolol partially mitigated changes in percent of B cells. 
Although there was no change in the peripheral white cell 
count in the group that received epinephrine at 200 /,g/kg 
per h, there was a 26% increase in the group treated with 
100/@%g per h (p = 0.005) and a 48% increase in the group 
that received both epinephrine and propranolol (p = 0.0008) 
(Table 1). However, there was a considerable decrease in the 
percent of MNLs in the low dose epinephrine group (8.4%, 
p - 0.0004) and a much greater decrease in the epinephrine- 
propranolol group (17%, p < 0.0001); however, the high dose 
of epinephrine caused only a slight decrease in the percent of 
MNLs (3.7%, p = 0.03) (Table 2). Despite this result, there 
was a trend toward lymphocytosis in both the low dose 
epinephrine group and the epinephrine-propranolol group. 
The number of natural killer cells increased 64% in the low 
dose epinephrine group (p = 0.002) and 84% in the high dose 
group (p = 0.03), with no effect with concomitant propranolol 
treatment. The remaining T cell subsets were not significantly 
altered. 
Tritiated thymidine incorporation after exposure to the T 
cell mitogen Con A was used as a measure of splenic lympho- 
cyte proliferation. Basal response, with no mitogen added, was 
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Figure 2. Percent of peripheral 
lymphocytes in rats treated with 
vehicle, epinephrine or epineph- 
rine plus propranolol. Results are 
mean percent 2 SEM. Two-tailed t
tests with Bonferroni corrections 
are labeled. Symbols as in Figure 1. 
*p - 0.05. **p - 0.01. ***p - 
0.001. ****p = 0.0001. 
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Table 1. Number  of Per iphera l  Lymphocyte  and Subsets Af ter  Four  Weeks of  Catecho lamine  Treatment  (mean + SEM [cells/txl]) 
Th Cells/ 
WBCs MNLs T, Cells T, Cells T h Cells NK Cells B Cells T s Cells 
Epinephrine 
Control 6,376 +- 207 5,417 + 168 3,678 ~ 183 1,602 + 9(I 2,818 -- 143 221 _+ 22 560 -+ 74 1.76 ± 0.12 
100 ,a~,'kg per h 8,055 - 513 6,061 + 287 4,064 z 213 1,792 _+ 107 3,025 -+ 168 362 + 35 683 -+ 60 1.74 -+ 0.1 
200 ,ag/kg per h 6,820 z 1,218 5.4(17 + 890 3,571 + 590 1,896 +- 374 2,519 -+ 411 406 -+ 140 734 + 171 1.41 ± 0.2 
Propranolol + 9,405 _+ 781 6,187 = 406 3,993 + 292 1,822 _+ 119 3,141 _+ 212 460 _+ 54 693 _+ 62 1.76 ± 0.1 
epinephrine 
Norepinephrine 
Control 7300 _+ 1,026 6,343 _~ 686 4,/191 +_ 289 1.778 + 277 3,400 _+ 313 225 +_ 38 499 _+ 108 2.12 _~ 0.2 
100 tzg/kg per h 7,944 + 592 6,611 + 592 4,399 +_ 445 1,718 + 180 3,424 -+ 286 271 2 42 598 -+ 83 2.06 ± 0.1 
200/xg/kg per h 8,227 -+ 909 6,890 + 867 4,222 + 587 1,793 -- 231 3,407 -+ 468 356 -+ 56 731 -+ 148 1.92 + 0.2 
MNLs - mononuclear leukocytes; NK ~ natural killer: Yh - helper T; 1"~ = suppressor T; T, - total T; WBCs - white blood cells. 
<5% of the maximal response (data not shown). The group 
that received epinephrine at100 ~g/kg per h showed a marked 
increase in Con A-induced tritiated thymidine uptake over the 
entire dose range compared with the control group (p < 0.01) 
(Fig. 3, top). This immune activation was not mitigated by 
propranolol. Epinephrine at 200 /xg/kg per h significantly 
curtailed proliferation (p < 0.001). There was also a trend 
toward an increased percent of interleukin-2 receptor-positive 
splenocytes after exposure to Con A (Fig. 3, bottom). This was 
not mitigated by concomitant administration f propranolol. 
One-day after pump implantation, rats were injected with 
the novel antigen KLH, and ELISA studies were performed on 
blood taken throughout the study. In the control rats, in vivo 
IgG antibody production to KLH intensified throughout the 
study (Fig. 4). The infusion of epinephrine t nded to diminish 
antibody production, which decreased even further on con- 
comitant administration of propranolol. 
Norepinephrine infusion. Infusion of norepinephrine 
caused significant atrophy of the spleen, resulting in an 
average 25% decrease in the spleen/body weight ratio (p -< 
0.0001) (Fig. 5). It also showed a trend toward dose- 
dependent hypertrophy of the left ventricle, although the 
heart/body weight ratio and left ventricle/body weight ratio 
were significantly altered only in the 200 tzg/kg per h group 
(heart/body weight ratio increased 29%, p = 0.0002 [Fig. 5]; 
left ventricle-body weight ratio increased 39%, p < 0.0001 [not 
shown]). Norepinephrine l vels in the blood varied over a wide 
range of values (Control group 612 + 110 pg/ml; infusion 
group 1,592 _+ 290 pg/ml). 
The percent of T cell subsets in the spleen is shown in Fig. 
6. There was a dose-dependent decrease in the percent of total 
T cells of 11% (p = 0.008) in the low dose group and 20% (p < 
0.00011 in the high dose group. Likewise, suppressor/cytotoxic 
T cells decreased by 25% (p = 0.02) and 38% (p < 0.0001). 
Helper T cells and natural killer cells tended to decrease with 
increasing norepinephrine. The helper T cell/suppressor T cell 
ratio increased from 1.80 _+ 0.18 to 2.47 _+ 0.17 in the high dose 
group, a change of 37% (p = 0.01). In contrast, the percent of 
B cells increased by 36% (p = 0.03) and 54% (p = 0.002). 
The peripheral white cell and MNL counts remained con- 
stant, as shown in Table 1. The percent of total T cells 
decreased, whereas natural killer cells increased, at the higher 
dosage (Table 2); the remaining T cell subsets howed no 
significant alterations. The B cells, however, also showed a 
tendency to increase. 
Neither dose of norepinephrine had any impact on spleno- 
cyte proliferation in response to Con A (Fig. 7, top). The 
percent of splenocytes that were positive for interleukin-2 
receptors was also unchanged (Fig. 7, bottom). 
The production of IgG antibodies to KLH was unaffected 
by the administration f norepinephrine (Fig. 8). 
Table 2. Peripheral Lymphocyte P rcentages After Four Weeks of Catecholamine Tr atment (mean _+ SEM) 
MNLs T t Cells T~ Cells T h Cells NK Cells B Cells 
Epinephrine 
Control 85 z 0.94 68 _+ 1.8 3(1 + 1.6 52 z 1.3 4.4 _+ 0.4 10 ± 1.2 
100/xg/kg per h 77 z 1.9 67 z 1.3 30 +_ 1.0 51/ -  1.5 5.9 -+ 0.4 l l  ± 1.0 
200/xg/kg per h 80 - 2.3 67 - 3.7 35 + 3.(1 47 _+ 3.6 7.6 ± 2.3 14 _* 3.7 
Propranolol + 68 - 2.6 64 _~ 2.3 30 -+- 1.1 51 + 1.4 7.4 ± 0.7 12 ± l. l  
epinephrine 
Norepinephrine 
Control 83 ~ 1.7 69 + 2.4 27 _+ 2.9 52 + 1.9 3.4 _+ 0.3 7 ± 1.4 
100 txg/kg per h 83 +_ 2.0 66 _+ 2.6 26 ÷ 1.7 52 ± 1.7 4.2 _+ 0.8 9 _+ 1.1 
200 txg/kg per h 82 + 2.7 60 _+ 1.8 27 + 1.7 49 _+ 1.7 5.6 t 0.9 10 ± 1.5 
Abbreviations as in Table 1. 
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Figure 3. Top, Concanavalin A (('on A) induced incorporation of 
tritiated thymidine at concentrations ranging from 0.5 to 8/,g/ml as a 
measure of splenocytc proliferation in rats treated with low (trianglesl 
and high (diamonds) dose epinephrine and epinephrine plus pm- 
pranolol (circles) compared with rats that received vehicle {squares). 
Results are mean value + SEM (epm tritiated thymidine incorpora- 
tion). Analysis of variance was used to correct for multiple compari- 
sons. Bottom, Percent interleukin-2 receptor (IL-2R) expression i rats 
treated with vehicle (cont). low dose epinephrine (cpi 1011) or epincph- 
rinc plus propranolol (prop/epi). Rcsuhs arc mean value + SIEM. 
Two-tailed t tests with Bonferroni corrections arc discussed in tcxl. 
Discuss ion  
Sympathetic nervous system regulation of immunity. 
Growing evidence suggests that the function of the immune 
system is partly under the control of the sympathetic nervous 
system (1-6). Anatomic studies have revealed an extensive 
presence of noradrcnergic fibers in both primary and second- 
ary lymphoid organs, innervating bolh the wtsculature and the 
Figure 4. lmmunoglobulin O response to keyhole lympet hemocyanin 
(KLtt) antigen in rats treated with vehicle, epinephrine or epinephrine 
plus propranoM, as measured by enzyme-linked imnmnosorbcnt 
assay. The KLH wets injected 1 day after pump in]plantation. Results 
are mean wduc _+ SEM. Analysis of variance was used to correct tbr 
multiple comparisons, abs - absorbancc. Symbols us in Figure 3. 
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Figure 5. Comparison of the effects of low (100 /,g,"kg per h [solid 
bars]) and high (200/x&,'kg per h [crosshatched bars]) dose norepi- 
nephrine infusion on splenic atrophy and cardiac hypertrophy, as 
measured by spleen (Spl)/%ody weight and heart (Ht)/body weight 
ratios. Control rats received vehicle (open bars). Results are mean 
value + SEM (mg tissue/g body weight). Two-tailed t tests with 
Bonferroni corrections are labeled. '~**p - 0.00l. ****p - 0.00(11. 
parcnchyma of the tissues (1). In these tissues, lymphocytes 
and sympathetic nerve endings form contacts at a distance that 
are even shorter than in a synapse (1-3). The presence of 
surface reccptors for sympathetic neurotransmitters makes 
lymphocytes usceptible to sympathetic stimulation. These 
rcceptors are of the beta-adrcnergic subtype and couple to 
adenylate cyclase to form the second-messenger cyclic adeno- 
sine monophosphate (AMP) (12,36,37). 
Short-term elevated catecholamine l vels, whether from 
catecholamine infusion (7,8,12,22-25), exercise (11-22) or 
acute myocardial infarction (26-28), led to leukocytosis after a 
beta-adrenoceptor-mediated splenic release of suppressor/ 
cytotoxic T cell and natural killer cells, subsets with the largest 
complement of surface beta-adrenoceptors (11,38-40). 
Changes in immunoregulato U cell traffic as well as elevation of 
cyclic AMP levels have been shown to inhibit mitogen- and 
antigen-induced T cell proliferation, cytotoxic T lymphocyte 
function, lymphokine secretion, production of interleukin-2 
and natural killer cell activity (13,41-43). These alterations can 
at least partially be blocked by previous treatment with beta- 
blockers or splenectomy (13,40). 
The effects of prolonged sympathetic stimulation on im- 
mune function are less clear, although there has been a long 
association between stress (with concomitant elevations of 
catecholamine l vels) and disease (44-48). Likewise, conges- 
tive heart failure, which is characterized by a prolonged 
elevation of circulating catecholamine l vels, has also been 
shown to induce immune abnormalities (29-34). 
In the present study, we examined the effects of prolonged 
infusion of the two catecholamines present in high concentra- 
tions in patients with congestive heart failure, namely epineph- 
rine and norepinephrine. In addition, we treated rats with 
propranolol as well as epinephrine in an attempt to distinguish 
between the effects of alpha- and beta-adrenoceptors. The 
dose ranges used were selected by taking 50% of the dose 
found to be lethal in the rats in early experimental trials. These 
dose ranges have been used by other investigators with hemo- 
dynamic effects that included increased heart rate, increased 
blood pressure and in some cases increased contractility 
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Figure 6. Percent of peripheral 
lymphocytes in rats treated with 
vehicle or norepinephrinc. Results 
are mean value +_ SEM. Two-tailed 
t tests with Bonferroni corrections 
are labeled. Symbols as in Figure 5. 
*p = 0.05. **p = 0.01. ****p - 
0.0001. 
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(2,10,23-25). The net change in serum levels of catecholamines 
after infusions in these animals are close to those usually found 
in patients with heart failure, especially after acute decompen- 
sation. In addition, these values are similar to the elevations 
found in animals 6 weeks after coronary arte~' ligation, when 
heart failure becomes apparent (49). 
Figure 7. Top, Splenocytc proliferative responses to va@ng concen- 
trations of concanavalin A (Con A) in rats treated with low (triangles) 
and high dose norepinephrine (circles) compared with rats that 
received vehicle (squares). Results are mean value + SEM (cpm 
tritiated thymidine incorporation). Analysis of variance was used to 
correct for multiple comparisons. Bottom, Percent interleukin-2 recep- 
tor (IL-2R) expression in rats treated with vehicle (cont) or low 
(nel00) or high dose norepinephrine (nc20()). Results arc mean 
value + SEM. Two-tailed t tests with Bonferroni corrections are 
labeled. ***p = (I.001. 
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Both epinephrine and norepinephrine caused a decrease in 
spleen weight and an increase in heart weight. Because epi- 
nephrine is much more potent at the betaa-receptor than 
norepinephrine, the finding that these changes were blocked by 
propranolol in the rats treated with epinephrine indicates that 
betaz-receptor mediation played a role in cell release, probably 
through changes in blood flow to the spleen. This is likely to be 
partially due to stimulation of splenic alphas-receptors that 
help mediate blood flow to the spleen (l,2). Norepinephrine 
has been shown (50,51) to stimulate beta2-receptors at high 
doses, which may explain some of the overlap of data. 
Alterations in the splenic composition of immunoregulatory 
cells after catecholamine infusion were quite dramatic. The 
cells released from the spleen, in a dose-dependent manner, 
were mainly suppressor/cytotoxic T and natural killer cells. 
With an increase in the helper T cell/suppressor T cell ratio, 
along with an increase in the proportion of splenic B cells, the 
cellular milieu may promote autoantibody formation. These 
Figure 8. lmmunoglobulin G response to keyhole limpet hemocyanin 
(KLH) antigen in rats treated with vehicle or norepinephrine, mea- 
sured using enzyme-linked immunosorbent assay. The KLH was 
injected 1 day after pump implantation. Results are mean value _+ 
SEM. Analysis of variance was used to correct for multiple compari- 
sons. abs - absorbance. Symbols as in Figure 7. 
1200[ " - - _ - -  
\ \  o 4 5/ 
£ 400 
,// 
0 3 ,10  14 17 2, 
Days after KLH injection 
108 HARRIS lET AL. JACC Vol. 26, No. l 
CATECHOLAMINE ELEVATION AND IMMUNlE FUNCTION July 1995:102-9 
alterations were unaffected by propranolo[, indicating other 
mechanisms, including stimulation of alpha-receptors, are pos- 
sible. This hypothesis was not tested. 
Despite the significant efflux of spleen cells, there were only 
minimal changes in the composition of the circulating lympho- 
cytes. Epinephrine induced an increase in white blood cell and 
MNL numbers at the low dose only but a decrease in the 
percent of MNLs, which was further decreased by propranolol. 
Norepinephrine had no effect. We found a significant increase 
in natural killer cells in the periphery, in all treatment groups, 
presumably released from the spleen. We observed no increase 
in either suppressor/cytotoxic T cell percent or number, which 
suggests hat splenocyte migration of this subtype was primar- 
ily to other lymphocyte reservoirs, such as thymus, bone 
marrow and lymph nodes. 
Proliferation of T lymphocytes i dependent on the pres- 
ence of interleukin-2 produced by activated T lymphocytes, 
primarily helper T cells (52). Epinephrine, at the low dose only, 
significantly enhanced the proliferative response to Con A and 
was unaffected by propranolol. One possible xplanation isthe 
tendency for the helper T cell/suppressor T cell ratio to 
increase, creating an environment favorable for antibody stim- 
ulation and cell proliferation. The high dose, however, was 
damaging to the cells, and proliferation was suppressed. This is 
consistent with previous tudies that found epinephrine to be 
cytotoxic in vitro (53). The data for splenic proliferation i the 
norepinephrine-treated rats is inconclusive, although the lower 
dose tended to reduce proliferation. 
In our examination of the antibody response, we turned 
next to the ability of the B cells to produce antibodies to the 
novel antigen KLH. Previous investigators (54,55) reported an 
enhancement of in vivo antibody production in response to 
epinephrine and postulated that the effect was through beta- 
receptor inhibition of rest suppressor T cells. In contrast, our 
findings indicate no variation from baseline as a result of 
saline-injected rats norepinephrine treatment. Epinephrine 
treatment tended to diminish antibody production slightly; this 
decrease was further augmented by propranolol. 
Implications of sympathetic-immune interactions in pro- 
gression and treatment of congestive heart failure: a hypoth- 
esis. As a consequence of inflammation rnecrosis (seen after 
an initial insult, such as a virus or a myocardial infarction), 
normally sequestered constituents may be released and be- 
come targets for an autoimmune r sponse. This insult might be 
low in magnitude, buffered by the host's normal immune 
defense mechanisms, especially with regard to cytotoxic T and 
natural killer cells. As left ventricular dysfunction begins to 
develop, activation of the sympathetic nervous system takes 
place to maintain effective cardiac output (56). This height- 
ened sympathetic activity also leads to alterations in T cell 
function, especially suppressor/cytotoxic T cell function, and in 
concert with a heightened helper T cell/suppressor T cell ratio, 
may present a milieu leading to B cell proliferation and 
subsequent perturbation fantibody synthesis, eventually ead- 
ing to the destruction of myocardial tissue (57-61). Sympa- 
thetic nervous ystem activity may also lead to cytokine gener- 
ation, which not only aids in autoantibody production, but 
might also lead to a depression of cardiac ontractility as well 
(62). An alternative hypothesis that a suppressive effect may 
take place in vivo, rendering the splenic and peripheral lym- 
phocyte populations less capable of responding to the in vitro 
challenge than their normal counterparts. Additionally, de- 
creased natural killer cell activity could allow for viral persis- 
tence as well as a general decrease in immune surveillance. 
Conclusions. Our study indicates that prolonged elevation 
of catecholamine l vels alters immune cell proliferation and 
differentiation i ways that differ greatly from those induced by 
short-term stimulation. In short-term stimulation there is a 
marked peripheral leukocytosis of predominantly suppressor/ 
cytotoxic T and natural killer cells and a general dampening of
the immune nervous system. With prolonged elevation of 
catecholamine levels as well as in cases of congestive heart 
failure, there appears to be adaptations of blood flow to the 
spleen in such that the cellular milieu promotes formation of 
autoantibodies. In addition there is altered generation of 
cytokines and perhaps other mediators of inflammation and 
immunity. We postulate that the shifts in immunoregulatory 
cell type and function seen in patients with congestive heart 
failure are due, in part, to long-standing increases in circulating 
catecholamines and may play an important role in the patho- 
genesis and progression of disease. 
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